Disposable blood expelling and hemostasis lantern ring

Abstract

The invention relates to the technical field of medical apparatus and instruments, and discloses a disposable blood expelling and hemostasis lantern ring which comprises the following raw materials in parts by mass: 30-50 parts of a hemostasis material group, 20-35 parts of an elastic material group, 15-25 parts of a degradation rate adjusting material group and 20-30 parts of a healing medicine material group, the hemostatic material group is prepared from the following raw materials in parts by mass: 7 to 11 parts of gelatin, 8 to 12 parts of polylactic acid, 5 to 10 parts of polycaprolactone, 6 to 13 parts of gelatin sponge and 1 to 4 parts of gelatin-gelatin butanone copolymer; the elastic material group is prepared from the following raw materials in parts by mass: 1 to 7 parts of polylactic acid-polycaprolactone copolymer, 1 to 5 parts of polycaprolactone-gelatin mixture, 6 to 13 parts of bioelastomer and 3 to 10 parts of gelatin-gelatin polyformaldehyde. By adding the elastic material group, the elastic property of the disposable blood expelling and hemostasis lantern ring can be improved, so that the defect that the strength and elasticity of an absorbable material are poorer than those of a traditional non-absorbable material can be overcome, and the hemostasis effect is improved.

Description

Technical Field

[0001] The invention relates to the technical field of medical devices, in particular to a disposable hemostatic hemostatic ring. Background Art

[0002] The main design of disposable hemostatic rings is to slowly absorb and integrate into the patient's body over a period of time without adversely affecting the patient's health. These rings are usually made of absorbable hemostatic materials, such as gelatin or polylactic acid. These absorbable materials gradually degrade in the patient's body without causing long-term retention or producing toxic substances.

[0003] Some absorbable materials in the disposable hemostatic ring in the prior art are not as strong and elastic as traditional non-absorbent materials. Therefore, due to the lack of elasticity, the performance of the hemostatic ring is affected, resulting in a decrease in the hemostatic effect. Summary of the invention

[0004] In view of the deficiencies of the prior art, the present invention provides a disposable hemostatic ring, which solves the problem that some absorbable materials in the disposable hemostatic ring in the prior art are not as strong and elastic as traditional non-absorbent materials, resulting in reduced hemostatic effect.

[0005] To achieve the above objectives, the present invention is implemented through the following technical scheme: a disposable hemostatic hemostatic ring comprises the following raw materials in mass fractions: 30 to 50 parts of a hemostatic material group, 20 to 35 parts of an elastic material group, 15 to 25 parts of a degradation rate regulating material group, and 20 to 30 parts of a healing drug material group.

[0006] Preferably, the hemostatic material group comprises the following raw materials in parts by weight: 7 to 11 parts of gelatin, 8 to 12 parts of polylactic acid, 5 to 10 parts of polycaprolactone, 6 to 13 parts of gelatin sponge, and 1 to 4 parts of gelatin-gelatin butanone copolymer.

[0007] Preferably, the elastic material group comprises the following raw materials in parts by mass: 1 to 7 parts of polylactic acid-polycaprolactone copolymer, 1 to 5 parts of polycaprolactone-gelatin mixture, 6 to 13 parts of bioelastomer, and 3 to 10 parts of gelatin-gelatin polyoxymethylene.

[0008] Preferably, the degradation rate regulating material group includes the following raw materials in parts by weight: 1 to 5 parts of protease, 1 to 3 parts of salt, 3 to 7 parts of chitosan, 2 to 6 parts of dextran, and 1 to 4 parts of seaweed polysaccharide.

[0009] Preferably, the healing drug material group includes the following raw materials in parts by weight: 3 to 8 parts of neomycin, 1 to 7 parts of acetaminophen, 4 to 10 parts of platelet-derived growth factor, 1 to 3 parts of vitamins, and 1 to 2 parts of heparin.

[0010] A method for preparing a disposable hemostatic hemostatic ring, according to the disposable hemostatic hemostatic ring according to claims 1-5, comprises the following steps: Step 1: First, the hemostatic material group and the degradation rate regulating material group are dried, the materials in the hemostatic material group and the degradation rate regulating material group are made into solids, and then the solids are crushed into particles, and the particles are screened to obtain particles of similar specifications; Step 2: firstly, polylactic acid, polycaprolactone and gelatin sponge are heated, then the heated materials are cooled, and after cooling, the particles of gelatin and gelatin-gelatin butanone copolymer are added, and the mixture is stirred after keeping the temperature for 20 to 30 minutes to obtain a mixture A; Step 3: Put polylactic acid-polycaprolactone copolymer and bioelastomer into a container and heat them to 100-150° C., keep them warm, stir them after keeping them warm for 20-25 minutes, cool them down after stirring, put polycaprolactone-gelatin mixture and gelatin-gelatin polyoxymethylene into the container after the temperature drops to 40-50° C., stir them again, and obtain mixture B after stirring; Step 4: Pour liquid protease into a container and heat it to 50-60°C, then pour salt into the container, and simultaneously put chitosan, glucan, and seaweed polysaccharide into the container and stir to obtain a mixture C; Step 5: Place neomycin, acetaminophen, platelet-derived growth factor, vitamins and heparin in a container and stir to obtain a mixture D; Step six: After heating mixture A to 50-70°C, add mixture B and mixture D and stir. After stirring for 20-30 minutes, add mixture C and stir. After stirring for 3-6 minutes, obtain mixture E. Cool mixture E, and perform injection molding on the cooled mixture E and then solidify it to obtain a disposable hemostatic ring.

[0011] Preferably, the polylactic acid, polycaprolactone and gelatin sponge in the step 2 are heated to 110-180° C., the cooling temperature in the step 2 is 50-60° C., and the stirring time in the step 2 is 10-15 minutes.

[0012] Preferably, the stirring time in step 4 is 5 to 8 minutes, and the temperature during stirring is always kept warm.

[0013] Preferably, the disposable hemostatic sleeve formed in step six is ​​surface treated to make it smooth, and then the disposable hemostatic sleeve with smooth surface is disinfected, a label is added to the disinfected disposable hemostatic sleeve, and the disposable hemostatic sleeve with the label is packed and boxed.

[0014] The disposable hemostatic ring comprises a hemostatic ring, the outer part of which is covered with a packaging bag, the top of which is pasted with a label, and the left side of which is provided with an opening groove.

[0015] The present invention provides a disposable hemostatic ring, which has the following beneficial effects: The present invention can increase the elasticity of the disposable hemostatic ring by adding an elastic material group, thereby overcoming the disadvantages of absorbable materials that are inferior to traditional non-absorbent materials in strength and elasticity, thereby avoiding affecting the performance of the hemostatic ring and improving the hemostatic effect.

[0016] The present invention adds a healing drug material group to the disposable hemostatic hemostatic ring, so that the disposable hemostatic hemostatic ring not only has the function of hemostasis, but also can accelerate the healing of wounds. Since acetaminophen is added to the healing drug material group, it can have an analgesic effect, thereby reducing the pain of patients and accelerating the recovery of patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 It is a cross-sectional view of the packaging bag in the present invention; Figure 2 It is a stereogram of the present invention.

[0018] Among them, 1. hemostatic ring; 2. packaging bag; 3. label sticker; 4. opening groove. DETAILED DESCRIPTION

[0019] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Example

[0020] The embodiment of the present invention provides a disposable hemostatic ring, comprising the following raw materials in mass fractions: 45 parts of a hemostatic material group, 30 parts of an elastic material group, 25 parts of a degradation rate regulating material group, and 25 parts of a healing drug material group.

[0021] The hemostatic material group comprises the following raw materials in parts by mass: 11 parts of gelatin, 10 parts of polylactic acid, 9 parts of polycaprolactone, 11 parts of gelatin sponge, and 4 parts of gelatin-gelatin butanone copolymer.

[0022] The elastic material group includes the following raw materials in parts by mass: 6 parts of polylactic acid-polycaprolactone copolymer, 4 parts of polycaprolactone-gelatin mixture, 10 parts of bioelastomer, and 10 parts of gelatin-gelatin polyoxymethylene.

[0023] The degradation rate regulating material group comprises the following raw materials in parts by weight: 5 parts of protease, 3 parts of salt, 7 parts of chitosan, 6 parts of dextran, and 4 parts of seaweed polysaccharide.

[0024] The healing drug material group includes the following raw materials in parts by weight: 7 parts of neomycin, 5 parts of acetaminophen, 8 parts of platelet-derived growth factor, 3 parts of vitamins, and 2 parts of heparin.

[0025] A method for preparing a disposable hemostatic hemostatic ring, according to the disposable hemostatic hemostatic ring according to claims 1-5, comprises the following steps: Step 1: First, the hemostatic material group and the degradation rate regulating material group are dried, the materials in the hemostatic material group and the degradation rate regulating material group are made into solids, and then the solids are crushed into particles, and the particles are screened to obtain particles of similar specifications; Step 2: firstly, polylactic acid, polycaprolactone and gelatin sponge are heated, then the heated materials are cooled, and after cooling, the particles of gelatin and gelatin-gelatin butanone copolymer are added, and the mixture is stirred after keeping the temperature for 26 minutes to obtain a mixture A; Step 3: Put polylactic acid-polycaprolactone copolymer and bioelastomer into a container and heat them to 130° C., keep them warm, stir them after keeping them warm for 22 minutes, cool them down after stirring, put polycaprolactone-gelatin mixture and gelatin-gelatin polyoxymethylene into the container after the temperature drops to 45° C., stir them again, and obtain mixture B after stirring; Step 4: Pour liquid protease into a container and heat it. After heating to 55°C, pour salt into the container. At the same time, put chitosan, glucan and seaweed polysaccharide into the container and stir to obtain a mixture C. Step 5: Place neomycin, acetaminophen, platelet-derived growth factor, vitamins and heparin in a container and stir to obtain a mixture D; Step six: After heating mixture A to 65°C, add mixture B and mixture D and stir. After stirring for 22 minutes, add mixture C and stir. After stirring for 6 minutes, obtain mixture E. Cool mixture E, and perform injection molding on the cooled mixture E and then solidify it to obtain a disposable hemostatic ring.

[0026] The polylactic acid, polycaprolactone and gelatin sponge in the step 2 are heated to 170° C., the cooling temperature in the step 2 is 55° C., and the stirring time in the step 2 is 11 minutes.

[0027] The stirring time in step 4 is 7 minutes, and the temperature during stirring is always kept warm.

[0028] The disposable hemostatic sleeve ring formed in step six is ​​subjected to surface treatment to make the disposable hemostatic sleeve smooth, and then the disposable hemostatic sleeve ring with smooth surface is disinfected, a label is added to the disinfected disposable hemostatic sleeve ring, and the disposable hemostatic sleeve ring with the label is packed and boxed.

[0029] The disposable hemostatic ring comprises a hemostatic ring, the outer part of which is covered with a packaging bag, the top of which is pasted with a label, and the left side of which is provided with an opening groove. Example

[0030] To distinguish the first embodiment, the present invention provides a disposable hemostatic hemostatic ring, including a raw material group by weight: 50 parts of a hemostatic material group, 35 parts of an elastic material group, 25 parts of a degradation rate regulating material group, and 30 parts of a healing drug material group, wherein the hemostatic material group includes 11 parts of gelatin, 12 parts of polylactic acid, 10 parts of polycaprolactone, 13 parts of gelatin sponge, and 4 parts of gelatin-gelatin butanone copolymer; the elastic material group includes 7 parts of polylactic acid-polycaprolactone copolymer, 5 parts of polycaprolactone-gelatin mixture, and 10 parts of raw materials. The following table was prepared in the same environment using a disposable hemostatic collar and similar method using animals of the same species with similar physical fitness, wound location and wound size, and 13 parts of bio elastomer, 10 parts of gelatin-gelatin polyformaldehyde, 5 parts of protease, 3 parts of salt, 7 parts of chitosan, 6 parts of dextran and 4 parts of seaweed polysaccharide in the degradation rate regulating material group, and 8 parts of neomycin, 7 parts of acetaminophen, 10 parts of platelet-derived growth factor, 3 parts of vitamins and 2 parts of heparin in the healing drug material group. Example

[0031] To distinguish the first embodiment, the present invention provides a disposable hemostatic ring, including a raw material group by weight: 42 parts of a hemostatic material group, 26 parts of an elastic material group, 23 parts of a degradation rate regulating material group, and 22 parts of a healing drug material group, wherein the hemostatic material group includes 9 parts of gelatin, 11 parts of polylactic acid, 7 parts of polycaprolactone, 13 parts of gelatin sponge, and 1 part of gelatin-gelatin butanone copolymer; the elastic material group includes 5 parts of polylactic acid-polycaprolactone copolymer, 5 parts of polycaprolactone-gelatin mixture, and 22 parts of a raw material group. The following table was prepared in the same environment using a disposable hemostatic collar and other similar animals with similar physical fitness, wound location and wound size, using 10 parts of bio elastomer, 6 parts of gelatin-gelatin polyformaldehyde, 3 parts of protease, 3 parts of salt, 7 parts of chitosan, 6 parts of dextran and 4 parts of seaweed polysaccharide in the degradation rate regulating material group, 5 parts of neomycin, 7 parts of acetaminophen, 7 parts of platelet-derived growth factor, 2 parts of vitamins and 1 part of heparin in the healing drug material group.

[0032] Hemostasis time / minute Wound healing time / day Embodiment 1 3 4 Embodiment 2 5 6 Embodiment 3 7 7 Traditional ring 11 10 Conclusion: From the data in the table, it can be seen that the disposable hemostatic hemostatic ring prepared by the formula in Example 1 is better than the disposable hemostatic hemostatic ring in the prior art and the disposable hemostatic hemostatic ring in Example 1 and Example 2, thereby improving the hemostatic effect and improving the patient's recovery efficiency.

[0033] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. The ingredients of the disposable hemostatic ring are characterized by: The invention comprises the following raw materials in mass fractions: 30 to 50 parts of a hemostatic material group, 20 to 35 parts of an elastic material group, 15 to 25 parts of a degradation rate regulating material group, and 20 to 30 parts of a healing drug material group.

2. The ingredients of the disposable hemostatic ring according to claim 1, characterized in that: The hemostatic material group comprises the following raw materials in parts by weight: 7-11 parts of gelatin, 8-12 parts of polylactic acid, 5-10 parts of polycaprolactone, 6-13 parts of gelatin sponge, and 1-4 parts of gelatin-gelatin butanone copolymer.

3. The ingredients of the disposable hemostatic ring according to claim 1, characterized in that: The elastic material group comprises the following raw materials in parts by weight: 1 to 7 parts of polylactic acid-polycaprolactone copolymer, 1 to 5 parts of polycaprolactone-gelatin mixture, 6 to 13 parts of bioelastomer, and 3 to 10 parts of gelatin-gelatin polyoxymethylene.

4. The ingredients of the disposable hemostatic ring according to claim 1, characterized in that: The degradation rate regulating material group comprises the following raw materials in parts by weight: 1 to 5 parts of protease, 1 to 3 parts of salt, 3 to 7 parts of chitosan, 2 to 6 parts of dextran, and 1 to 4 parts of seaweed polysaccharide.

5. The ingredients of the disposable hemostatic ring according to claim 1, characterized in that: The healing drug material group comprises the following raw materials in parts by weight: 3 to 8 parts of neomycin, 1 to 7 parts of acetaminophen, 4 to 10 parts of platelet-derived growth factor, 1 to 3 parts of vitamins, and 1 to 2 parts of heparin.

6. A method for preparing a disposable hemostatic hemostatic ring, according to the disposable hemostatic hemostatic ring according to claims 1-5, characterized in that: The following steps are involved: Step 1: First, the hemostatic material group and the degradation rate regulating material group are dried, the materials in the hemostatic material group and the degradation rate regulating material group are made into solids, and then the solids are crushed into particles, and the particles are screened to obtain particles of similar specifications; Step 2: firstly, polylactic acid, polycaprolactone and gelatin sponge are heated, then the heated materials are cooled, and after cooling, the particles of gelatin and gelatin-gelatin butanone copolymer are added, and the mixture is stirred after keeping the temperature for 20 to 30 minutes to obtain a mixture A; Step 3: Put polylactic acid-polycaprolactone copolymer and bioelastomer into a container and heat them to 100-150° C., keep them warm, stir them after keeping them warm for 20-25 minutes, cool them down after stirring, put polycaprolactone-gelatin mixture and gelatin-gelatin polyoxymethylene into the container after the temperature drops to 40-50° C., stir them again, and obtain mixture B after stirring; Step 4: Pour liquid protease into a container and heat it to 50-60°C, then pour salt into the container, and simultaneously put chitosan, glucan, and seaweed polysaccharide into the container and stir to obtain a mixture C; Step 5: Place neomycin, acetaminophen, platelet-derived growth factor, vitamins and heparin in a container and stir to obtain a mixture D; Step six: After heating mixture A to 50-70°C, add mixture B and mixture D and stir. After stirring for 20-30 minutes, add mixture C and stir. After stirring for 3-6 minutes, obtain mixture E. Cool mixture E, and perform injection molding on the cooled mixture E and then solidify it to obtain a disposable hemostatic ring.

7. The method for preparing a disposable hemostatic ring according to claim 6, characterized in that: The polylactic acid, polycaprolactone and gelatin sponge in the step 2 are heated to 110-180° C., the cooling temperature in the step 2 is 50-60° C., and the stirring time in the step 2 is 10-15 minutes.

8. The method for preparing a disposable hemostatic ring according to claim 6, characterized in that: The stirring time in step 4 is 5 to 8 minutes, and the temperature during stirring is always kept warm.

9. The method for preparing a disposable hemostatic ring according to claim 6, characterized in that: The disposable hemostatic sleeve ring formed in step six is ​​subjected to surface treatment to make the disposable hemostatic sleeve smooth, and then the disposable hemostatic sleeve ring with smooth surface is disinfected, a label is added to the disinfected disposable hemostatic sleeve ring, and the disposable hemostatic sleeve ring with the label is packed and boxed.

10. A disposable hemostatic ring, comprising a hemostatic ring (1), characterized in that: The hemostatic ring (1) is externally sleeved with a packaging bag (2), a label (3) is adhered to the top of the packaging bag (2), and an opening groove (4) is provided on the left side of the packaging bag (2).

Images